Bio Essence Past Earnings Performance
Past criteria checks 0/6
Bio Essence has been growing earnings at an average annual rate of 19.4%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been declining at an average rate of 0.7% per year.
Key information
19.4%
Earnings growth rate
20.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -0.7% |
| Return on equity | n/a |
| Net Margin | -145.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Bio Essence makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -1 | 1 | 0 |
| 30 Sep 23 | 1 | -1 | 1 | 0 |
| 30 Jun 23 | 1 | -1 | 1 | 0 |
| 31 Mar 23 | 1 | -1 | 1 | 0 |
| 31 Dec 22 | 1 | -1 | 1 | 0 |
| 30 Sep 22 | 1 | -1 | 1 | 0 |
| 30 Jun 22 | 1 | -1 | 1 | 0 |
| 31 Mar 22 | 1 | -1 | 1 | 0 |
| 31 Dec 21 | 1 | -1 | 1 | 0 |
| 30 Sep 21 | 1 | -1 | 1 | 0 |
| 30 Jun 21 | 1 | -1 | 1 | 0 |
| 31 Mar 21 | 1 | -1 | 1 | 0 |
| 31 Dec 20 | 1 | -1 | 1 | 0 |
| 30 Sep 20 | 1 | -1 | 1 | 0 |
| 30 Jun 20 | 1 | -1 | 2 | 0 |
| 31 Mar 20 | 1 | -2 | 2 | 0 |
| 31 Dec 19 | 1 | -2 | 2 | 0 |
| 30 Sep 19 | 1 | -2 | 2 | 0 |
| 30 Jun 19 | 1 | -1 | 2 | 0 |
| 31 Mar 19 | 1 | -1 | 2 | 0 |
| 31 Dec 18 | 1 | -1 | 2 | 0 |
| 31 Dec 17 | 1 | -2 | 2 | 0 |
Quality Earnings: BIOE is currently unprofitable.
Growing Profit Margin: BIOE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOE is unprofitable, but has reduced losses over the past 5 years at a rate of 19.4% per year.
Accelerating Growth: Unable to compare BIOE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: BIOE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.